vyvgart
argenx - efgartigimod alfa - myasthenia gravis - imunosupresoare - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.
vaccamast, suspenzie intramamară
ooo npp agrofarm, rusia - dioxidină; - soluţie intramamară
ultomiris
alexion europe sas - ravulizumab - hemoglobinurie, paroxismal - imunosupresoare selective - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
soliris
alexion europe sas - eculizumab - hemoglobinurie, paroxismal - imunosupresoare - soliris este indicat la adulți și copii pentru tratamentul:hemoglobinurie paroxistică nocturnă (hpn). dovezi de beneficii clinice este demonstrată la pacienții cu hemoliză cu simptom clinic(s) indică un grad înalt de activitate a bolii, indiferent de transfuzie istorie (a se vedea secțiunea 5. atipic sindrom hemolitic-uremic (ahus). soliris este indicat la adulți pentru tratamentul:refractare generalizate miastenia gravis (gmg) la pacienții care sunt anti-receptorilor de acetilcolină (achr) anticorpi-pozitiv (a se vedea secțiunea 5. oftalmoneuromielită optica tulburare de spectru (nmosd) la pacienții care sunt anti-aquaporin-4 (aqp4) anticorpi pozitiv cu un curs recurente ale bolii.
zevesin 5 mg
zentiva, k.s. - republica ceha - solifenacinum succinat - compr. film. - 5mg - urologice med. pt. frecv. urinara crescuta si incontinenta
zevesin 10 mg
zentiva, k.s. - republica ceha - solifenacinum succinat - compr. film. - 10mg - urologice med. pt. frecv. urinara crescuta si incontinenta
milprazon 4mg/10mg, comprimate filmate pentru pisici de talie mică şi pisicuţe cu greutatea corporală de cel puţin 0,5kg
krka d.d.novo mesto, slovenia - milbemycin - comprimate
zevesin 10 mg comprimate filmate
zentiva k.s. - solifenacinum succinas - comprimate filmate - 10 mg
microgran co 5% bmp, aditiv furajer
dox-al.s.p.a., italia - carbonat - granule - rumegătoare, ecvine, lagomorfe, rozătoare, erbivore, рептилии, mamifere дин grădinele zoologice
ismigen 7 mg comprimate sublinguale
gm pharmaceuticals ltd. - combinaţie - comprimate sublinguale - 7 mg